You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

NATRECOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Natrecor patents expire, and what generic alternatives are available?

Natrecor is a drug marketed by Scios Llc and is included in one NDA.

The generic ingredient in NATRECOR is nesiritide. There are two drug master file entries for this compound. Additional details are available on the nesiritide profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NATRECOR?
  • What are the global sales for NATRECOR?
  • What is Average Wholesale Price for NATRECOR?
Summary for NATRECOR
Drug patent expirations by year for NATRECOR
Drug Prices for NATRECOR

See drug prices for NATRECOR

Recent Clinical Trials for NATRECOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Virginia Commonwealth UniversityPhase 4
John C BurnettPhase 1/Phase 2
Mayo ClinicPhase 1/Phase 2

See all NATRECOR clinical trials

US Patents and Regulatory Information for NATRECOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc NATRECOR nesiritide FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NATRECOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Scios Llc NATRECOR nesiritide FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 5,114,923 ⤷  Subscribe
Scios Llc NATRECOR nesiritide FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 6,974,861 ⤷  Subscribe
Scios Llc NATRECOR nesiritide FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 5,674,710 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NATRECOR

See the table below for patents covering NATRECOR around the world.

Country Patent Number Title Estimated Expiration
Germany 68923878 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 8912069 ⤷  Subscribe
Austria 126522 ⤷  Subscribe
Ireland 68889 Recombinant techniques for production of novel natriuretic and vasodilator peptides ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

NATRECOR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Natrecor

Introduction

Natrecor, also known as nesiritide, is a natriuretic peptide indicated for the treatment of patients with acutely decompensated heart failure who experience dyspnea at rest or with minimal activity. Here, we will delve into the market dynamics and financial trajectory of Natrecor, exploring its clinical significance, market performance, and the factors influencing its financial outlook.

Clinical Significance and Indications

Natrecor is designed to reduce pulmonary capillary wedge pressure and improve short-term symptoms of dyspnea in patients with acutely decompensated heart failure. The recommended dosing regimen includes a 2 mcg/kg IV bolus followed by an intravenous infusion of 0.01 mcg/kg/min[2].

Market Entry and Initial Reception

Natrecor was approved by the FDA in 2001 and initially received significant attention for its potential to manage acute heart failure. However, its market reception was mixed due to concerns over its efficacy and safety profile.

Clinical Trials and Outcomes

Several clinical trials, including the VMAC and ASCEND-HF trials, have evaluated the efficacy and safety of Natrecor. These trials showed that Natrecor reduced pulmonary capillary wedge pressure and improved dyspnea symptoms but also highlighted potential adverse effects such as hypotension and worsening renal function[1][2].

Hypotension

The incidence of symptomatic hypotension was a significant concern, with rates similar to or slightly higher than those of comparator treatments like nitroglycerin. However, the duration of hypotension was longer with Natrecor[1][2].

Renal Function

Natrecor may decrease renal function, as indicated by increases in serum creatinine. This effect was more pronounced at higher doses and in patients with severe heart failure[1].

Mortality

A meta-analysis of seven clinical trials showed that Natrecor did not increase mortality in patients with acute decompensated heart failure at 30 or 180 days[1].

Market Performance

Despite its clinical benefits, Natrecor's market performance has been impacted by several factors:

Competition

The heart failure market is highly competitive, with established treatments such as ACE inhibitors, beta-blockers, and other vasodilators. Natrecor's unique mechanism of action did not necessarily translate into a significant market share due to these existing therapies[4].

Safety Concerns

The adverse effects associated with Natrecor, particularly hypotension and renal impairment, have limited its adoption. These safety concerns have led to cautious prescribing practices and reduced its market potential[1][2].

Regulatory Scrutiny

The FDA's standards for drug approval and post-marketing surveillance have also influenced Natrecor's market dynamics. The ASCEND-HF trial, for example, was a large-scale study aimed at addressing concerns about Natrecor's safety and efficacy[5].

Financial Trajectory

The financial performance of Natrecor has been challenging due to several factors:

Initial Hype and Subsequent Decline

Upon its introduction, Natrecor generated significant interest and initial sales. However, as safety concerns and mixed clinical trial results emerged, its sales declined. The drug failed to meet the high expectations set during its launch phase[4].

Revenue Impact

The decline in sales has had a direct impact on the revenue generated by Natrecor. Despite being part of a large pharmaceutical portfolio, the drug's financial contribution has been limited compared to other products in the same therapeutic area.

Cost of Clinical Trials

The extensive clinical trials, such as the ASCEND-HF trial, have been costly. These expenses, combined with the reduced revenue, have affected the overall financial trajectory of Natrecor[5].

Market Dynamics and Future Outlook

The market dynamics for Natrecor are complex, influenced by clinical, regulatory, and economic factors:

Changing Treatment Paradigms

The treatment landscape for heart failure is evolving, with new therapies and guidelines emerging. Natrecor's place in this landscape is uncertain, as newer treatments may offer better safety and efficacy profiles[4].

Regulatory Environment

The regulatory environment continues to play a crucial role in Natrecor's market dynamics. Any changes in FDA guidelines or post-marketing surveillance requirements could further impact its use and sales.

Patient and Physician Preferences

Patient and physician preferences also influence the market. The perceived benefits and risks of Natrecor, as well as its ease of use and integration into existing treatment protocols, will continue to shape its market trajectory.

Key Takeaways

  • Clinical Significance: Natrecor reduces pulmonary capillary wedge pressure and improves short-term dyspnea symptoms but is associated with hypotension and renal impairment.
  • Market Performance: Despite initial hype, Natrecor's market performance has been impacted by safety concerns, competition, and regulatory scrutiny.
  • Financial Trajectory: The drug's financial performance has been challenging due to declining sales, high clinical trial costs, and a competitive market.
  • Future Outlook: The future of Natrecor depends on evolving treatment paradigms, regulatory changes, and patient/physician preferences.

FAQs

What is Natrecor used for?

Natrecor is used for the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity.

What are the common side effects of Natrecor?

Common side effects include hypotension and worsening renal function, as indicated by increases in serum creatinine.

How does Natrecor compare to other heart failure treatments?

Natrecor's unique mechanism of action sets it apart, but its adoption has been limited by safety concerns and the presence of established therapies.

What clinical trials have been significant for Natrecor?

The VMAC and ASCEND-HF trials have been pivotal in evaluating Natrecor's efficacy and safety.

Has Natrecor been associated with increased mortality?

No, meta-analyses have shown that Natrecor does not increase mortality in patients with acute decompensated heart failure at 30 or 180 days.

Sources

  1. Drugs.com: Natrecor: Package Insert / Prescribing Information.
  2. FDA: Natrecor - accessdata.fda.gov.
  3. GlaxoSmithKline: Annual Report 2004.
  4. PubMed: The rise and fall of Natrecor for congestive heart failure.
  5. Small-Cap Research: Focus Turns To Post-Acute Indication For Cenderitide.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.